Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
1
pubmed:dateCreated
1978-2-23
pubmed:abstractText
Trimazosin is a new quinazoline derivative vasodilator previously thought to act primarily on resistance vessels. Vasodilators characteristically improve hemodynamics in patients with left ventricular failure. Trimazosin in single oral doses of 100 to 300 mg was given to 6 patients with class III-IV congestive heart failure due to ischemic or primary cardiomyopathy and hemodynamics were monitored for 4 hr. Onset of action was apparent at 1 hr, with peak effects occurring at 1 to 3 hr and significant effects persisting at 4 hr. At peak, mean systemic arterial pressure fell from 91.2 +/- 4.8 (SEM) to 82.5 +/- 2.5 mm Hg (p less than 0.05), heart rate was unchanged, and cardiac index (by dye dilution) was up to 2.12 +/- 0.27 from 1.76 +/- 0.33 L/min/m2 (NS). Right heart pressures (by Swan-Ganz catheterization) were reduced, right atrial, 11.3 +/- 2.1 to 8.7 +/- 1.6 mm Hg (p less than 0.02), mean pulmonary arterial pressure, 40.7 +/- 4.6 to 33.8 +/- 4.8 mm Hg (p less than 0.01), and pulmonary arterial wedge, 30.7 +/- 4.5 to 23.8 +/- 5.0 mm Hg (p less than 0.01). Forearm venous capacitance, by occlusion plethysmography, increased from 0.83 +/- 0.18 ml/100 gm to 1.12 +/- 0.22 ml/100 gm after trimazosin (p less than 0.01). Trimazosin is an orally effective vasodilator that acts on both resistance and capacitance vessels in patients with congestive heart failure.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
AIM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Jan
pubmed:issn
0009-9236
pubmed:author
pubmed:issnType
Print
pubmed:volume
23
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
11-8
pubmed:dateRevised
2007-11-15
pubmed:meshHeading
pubmed:year
1978
pubmed:articleTitle
Hemodynamic effects of trimazosin in patients with left ventricular failure.
pubmed:publicationType
Journal Article, Research Support, U.S. Gov't, P.H.S.